Evidence map›Paper›PMID 32312846›Full record

ArticleRNA (New York, N.Y.)2020

Antisense targeting of decoy exons can reduce intron retention and increase protein expression in human erythroblasts.

Marilyn Parra, Weiguo Zhang, Jonathan Vu, Mark DeWitt, John G Conboy

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RNA (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Frontiers in genetics · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Marilyn ParraBiological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA.
Weiguo ZhangBiological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA.
Jonathan VuInnovative Genomics Institute, University of California, Berkeley, California, USA.
Mark DeWittInnovative Genomics Institute, University of California, Berkeley, California, USA.
John G ConboyBiological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA.
Lawrence Berkeley National Laboratory · USInnovative Genomics Institute · US

Funding

Intron Retention Mechanisms that Regulate Erythroid SF3B1 Gene ExpressionR01DK108020 · NIDDK · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI CONBOY, JOHN G · 2016 to 2018
$1.1M
NIDDK NIH HHS R01 DK108020
6 · The paper itself

Abstract

The decoy exon model has been proposed to regulate a subset of intron retention (IR) events involving predominantly larger introns (>1 kb). Splicing reporter studies have shown that decoy splice sites are essential for activity, suggesting that decoys act by engaging intron-terminal splice sites and competing with cross-intron interactions required for intron excision. The decoy model predicts that antisense oligonucleotides may be able to block decoy splice sites in endogenous pre-mRNA, thereby reducing IR and increasing productive gene expression. Indeed, we now demonstrate that targeting a decoy 5' splice site in the O-GlcNAc transferase (

Indexed as

Alternative SplicingCells, CulturedErythroblastsExonsHumansIntronsN-AcetylglucosaminyltransferasesOligonucleotides, AntisenseRNA PrecursorsRNA Splice SitesRNA Splicing FactorsN-AcetylglucosaminyltransferasesO-GlcNAc transferaseOligonucleotides, AntisenseRNA PrecursorsRNA Splice SitesRNA Splicing Factorsalternative splicingdecoy exonerythroid gene expressionintron retentionSF3B1

Identifiers

PMID32312846
PMCPMC7373989
OpenAlexW3016500536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.